472 related articles for article (PubMed ID: 29999213)
1. Sirolimus as initial therapy for kaposiform hemangioendothelioma and tufted angioma.
Wang H; Guo X; Duan Y; Zheng B; Gao Y
Pediatr Dermatol; 2018 Sep; 35(5):635-638. PubMed ID: 29999213
[TBL] [Abstract][Full Text] [Related]
2. Low dose sirolimus treatment for refractory tufted angioma and congenital kaposiform hemangioendothelioma, both with Kasabach-Merritt phenomenon.
Mariani LG; Schmitt IR; Garcia CD; Kiszewski AE
Pediatr Blood Cancer; 2019 Aug; 66(8):e27810. PubMed ID: 31087627
[No Abstract] [Full Text] [Related]
3. Sirolimus therapy for children with problematic kaposiform haemangioendothelioma and tufted angioma.
Tasani M; Ancliff P; Glover M
Br J Dermatol; 2017 Dec; 177(6):e344-e346. PubMed ID: 28485019
[No Abstract] [Full Text] [Related]
4. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Wang Z; Li K; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2014 Aug; 61(8):1518-9. PubMed ID: 24482015
[No Abstract] [Full Text] [Related]
5. Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabach-Merritt phenomenon.
Chiu YE; Drolet BA; Blei F; Carcao M; Fangusaro J; Kelly ME; Krol A; Lofgren S; Mancini AJ; Metry DW; Recht M; Silverman RA; Tom WL; Pope E
Pediatr Blood Cancer; 2012 Nov; 59(5):934-8. PubMed ID: 22648868
[TBL] [Abstract][Full Text] [Related]
6.
Russell TB; Rinker EK; Dillingham CS; Givner LB; McLean TW
Pediatrics; 2018 Apr; 141(Suppl 5):S421-S424. PubMed ID: 29610164
[TBL] [Abstract][Full Text] [Related]
7. Rapidly enlarging "bruise" on the back of an infant. Kaposiform hemangioendothelioma complicated by Kasabach-Merritt syndrome.
Chan S; Cassarino DS
JAMA Dermatol; 2013 Nov; 149(11):1337-8. PubMed ID: 24005816
[No Abstract] [Full Text] [Related]
8. Sirolimus for Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon in Two Infants.
Wang Y; Kong L; Sun B; Cui J; Shen W
J Craniofac Surg; 2020 Jun; 31(4):1074-1077. PubMed ID: 32176003
[TBL] [Abstract][Full Text] [Related]
9. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
10. Successful treatment of Kasabach-Merritt phenomenon arising from Kaposiform hemangioendothelioma by sirolimus.
Wang Z; Li K; Dong K; Xiao X; Zheng S
J Pediatr Hematol Oncol; 2015 Jan; 37(1):72-3. PubMed ID: 24309604
[No Abstract] [Full Text] [Related]
11. Treatment of kaposiform hemangioendothelioma and tufted angioma.
Liu XH; Li JY; Qu XH; Yan WL; Zhang L; Yang C; Zheng JW
Int J Cancer; 2016 Oct; 139(7):1658-66. PubMed ID: 27252149
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus ointment for the treatment of superficial kaposiform hemangioendothelioma and tufted angioma.
Zhang X; Yang K; Chen S; Ji Y
J Dermatol; 2019 Oct; 46(10):898-901. PubMed ID: 31373046
[TBL] [Abstract][Full Text] [Related]
13. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon in an infant: Successful treatment with prednisolone, vincristine, and addition of sirolimus.
Cashell J; Smink GM; Helm K; Xavier F
Pediatr Blood Cancer; 2018 Dec; 65(12):e27305. PubMed ID: 30070028
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
15. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
16. Medical management of tumors associated with Kasabach-Merritt phenomenon: an expert survey.
Tlougan BE; Lee MT; Drolet BA; Frieden IJ; Adams DM; Garzon MC
J Pediatr Hematol Oncol; 2013 Nov; 35(8):618-22. PubMed ID: 23774156
[TBL] [Abstract][Full Text] [Related]
17. Kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon: from vincristine to sirolimus.
Jahnel J; Lackner H; Reiterer F; Urlesberger B; Urban C
Klin Padiatr; 2012 Oct; 224(6):395-7. PubMed ID: 23070861
[No Abstract] [Full Text] [Related]
18. Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: successful treatment with sirolimus.
Reichel A; Hamm H; Wiegering V; Wiewrodt B; Neubauer H; Ernestus K; Winkler B
J Dtsch Dermatol Ges; 2017 Mar; 15(3):329-331. PubMed ID: 28220608
[No Abstract] [Full Text] [Related]
19. Sirolimus for treatment of Kaposiform haemangioendothelioma with Kasabach-Merritt phenomenon: a retrospective cohort study.
Zhang G; Chen H; Gao Y; Liu Y; Wang J; Liu XY
Br J Dermatol; 2018 May; 178(5):1213-1214. PubMed ID: 29388191
[No Abstract] [Full Text] [Related]
20. [Refractory kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: clinical analysis of 10 cases].
Zhang GL; Gao Y; Liu Y; Gu F; Su W; Qin Q; Chen JY; Zhang HH; Yang J; Liu XY
Zhonghua Er Ke Za Zhi; 2017 Sep; 55(9):700-704. PubMed ID: 28881518
[No Abstract] [Full Text] [Related]
[Next] [New Search]
